Home
/
Immix Biopharma, Inc.
/
Financials
/
Quarterly
Immix Biopharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Immix Biopharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Dec 8, 2022
$20.00M
Aug 8, 2025
Q3
2025
Dec 8, 2022
$20.00M
Nov 7, 2025
Q1
2025
Dec 8, 2022
$20.00M
May 8, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.59M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($6.62M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($4.54M)
May 8, 2025
Q3
2025
Sep 30, 2024
($7.15M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($4.39M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($5.26M)
May 8, 2025
Q3
2024
Sep 30, 2023
($4.28M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($3.58M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($2.48M)
May 9, 2024
Q3
2023
Sep 30, 2022
($1.54M)
Nov 13, 2023
Q3
2022
Jun 30, 2022
($1.56M)
Nov 9, 2022
Q2
2023
Jun 30, 2022
($1.56M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($1.33M)
May 12, 2023
Q2
2022
Mar 31, 2022
($1.33M)
Aug 12, 2022
Q3
2022
Mar 31, 2022
($1.33M)
Nov 9, 2022
Q3
2022
Sep 30, 2021
($403.3K)
Nov 9, 2022
Q3
2022
Jun 30, 2021
($208.6K)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($208.6K)
Aug 12, 2022
Q3
2022
Mar 31, 2021
($1.02M)
Nov 9, 2022
Q1
2022
Mar 31, 2021
($1.02M)
May 13, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.66M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($6.72M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($4.68M)
May 8, 2025
Q3
2025
Sep 30, 2024
($7.39M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($4.70M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($5.59M)
May 8, 2025
Q3
2024
Sep 30, 2023
($4.52M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($3.72M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($2.52M)
May 9, 2024
Q3
2023
Sep 30, 2022
($1.53M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($1.56M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($1.33M)
May 12, 2023
Q3
2022
Sep 30, 2021
($348.0K)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($243.2K)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($162.5K)
May 13, 2022